ArticlebioRxiv : the preprint server for biology2024
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Open access · greenAbstract readPreprint
In one paragraph
Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 8 institutions in 2 countries.
Or-Yam RevachMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Angelina M CicerchiaMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Ofir ShorerDepartment of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Boryana PetrovaHarvard Medical School, Boston, MA, USA.
Seth AndersonMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Joshua ParkBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Lee ChenComputer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA, USA.
Arnav MehtaMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Samuel J WrightBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Niamh McNameeHarvard Medical School, Boston, MA, USA.
Aya Tal-MasonHarvard Medical School, Boston, MA, USA.
Giulia CattaneoDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Payal TiwariBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Hongyan XieMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Johanna M SweereTeiko Bio, Salt Lake City, UT, USA.
Li-Chun ChengTeiko Bio, Salt Lake City, UT, USA.
Natalia SigalTeiko Bio, Salt Lake City, UT, USA.
Elizabeth EnricoTeiko Bio, Salt Lake City, UT, USA.
Marisa MiljkovicTeiko Bio, Salt Lake City, UT, USA.
Shane A EvansTeiko Bio, Salt Lake City, UT, USA.
Ngan NguyenTeiko Bio, Salt Lake City, UT, USA.
Mark E WhiddenTeiko Bio, Salt Lake City, UT, USA.
Ramji SrinivasanTeiko Bio, Salt Lake City, UT, USA.
Matthew H SpitzerTeiko Bio, Salt Lake City, UT, USA.
Yi SunMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Tatyana SharovaDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Aleigha R LawlessDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
William A MichaudDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Martin Q RasmussenMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Jacy FangMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Claire A PalinMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Feng ChenDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Xinhui WangHarvard Medical School, Boston, MA, USA.
Cristina R FerroneHarvard Medical School, Boston, MA, USA.
Donald P LawrenceMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Ryan J SullivanMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
David LiuHarvard Medical School, Boston, MA, USA.
Uma M SachdevaHarvard Medical School, Boston, MA, USA.
Debattama R SenMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Keith T FlahertyMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Robert T MangusoMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Lloyd BodMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Manolis KellisDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0001-7113-9630
Genevieve M BolandHarvard Medical School, Boston, MA, USA.
Keren YizhakDepartment of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Jiekun YangComputer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-0920-052X
Naama KanarekHarvard Medical School, Boston, MA, USA.ORCID 0000-0002-2068-3908
Moshe Sade-FeldmanMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Nir HacohenMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Russell W JenkinsMass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Broad Institute · USHarvard University · USTeikoku Pharma (United States) · USBoston Children's Hospital · USMassachusetts Institute of Technology · USTechnion – Israel Institute of Technology · ILCancer Research Institute · USCedars-Sinai Medical Center · US
Funding
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MT cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancerR01DE028172 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2018 to 2022
$1.9MPrevention of post-therapy breast cancer metastasisR01CA226981 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2019 to 2023
$1.8MDissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyK08CA234458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LIU, DAVID · 2018 to 2022
$1.2MEx Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor SpheroidsK08CA226391 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JENKINS, RUSSELL WILLIAM · 2018 to 2022
$946kNCI NIH HHS K08 CA226391NCI NIH HHS K08 CA234458NCI NIH HHS K12 CA087723NCI NIH HHS R01 CA226981NIDCR NIH HHS R01 DE028172
Abstract
A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma
Indexed as
3D microfluidic cultureCD38cytokinesimmunotherapyNAD+organotypic tumour spheroidsPD-1T cell exhaustion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.